Therapeutic effects of L/N type calcium channel blocker cilnidipine and L type calcium channel blockers on hypertensive patients with chronic kidney disease

Therapeutic effects of L/N type calcium channel blocker cilnidipine and L type calcium channel blockers on hypertensive patients with chronic kidney disease - Therapeutic effects of L/N type calcium channel blocker cilnidipine and L type calcium channel blockers on hypertensive patients with chronic kidney disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001593

Enrollment

Registered

2008-12-22

Start date

2008-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Chronic kidney disease

Interventions

Cilnidipine (L/N) group: Change already prescribed calcium channel blockers other than cilnidipine to daily dosing of cilnidipine 10 mg daily for 48 weeks, and dosage may be modulated accroding to the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with chronic kidney disease stages 3, 4, and 5 (eGFR<=60 ml/min/1.73 m2), 2. who are already treated with inhibitors of renin-angiotensin system (ACEi and/or ARB), 3. and are also already treated with calcium channel blockers other than cilnidipine.

Exclusion criteria

Exclusion criteria: 1. Patients already treated with cilnidipine, 2. History of hypersensitivity to cilnidipine, 3. Severe hypertension (clinic BP more than 180/100 mmHg), 4. Severe liver disorder, or severe biliary atresia, 5. Pregnant women, or women suspected of being pregnant.

Design outcomes

Primary

Measure	Time frame
1. Clinic blood pressure. 2. Ambulatory blood pressure monitoring. 3. Renal function: eGFR, urinary protein/albuminon excretion. 4. Renin-angiotensin system, inflammatory and oxidative stress markers, PRA, urinary angiotensinogen, plasma cathecholamine. 5. Cardiac function: BNP, UCG. 6. Vascular function: ABI/baPWV.	—

Countries

Japan

Contacts

Public ContactSatoshi UMEMURA

Yokohama City University Graduate School of Medicine Deaprtment of Medical Science

sumemura@med.yokohama-cu.ac.jp045-787-2633

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026